Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

This study is testing a combination of relmacabtagene autoleucel (a CAR-T cell therapy targeting CD19) together with sintilimab (an immune checkpoint blocker) in patients with relapsed or refractory B-cell lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with DLBCL, follicular lymphoma (FL), or mantle cell lymphoma (MCL) confirmed by biopsy with CD19-positive tumors - Your cancer has come back or not responded to prior treatment - You have at least one measurable or evaluable tumor - Your overall health is adequate (ECOG 0–2) and expected survival is at least 3 months - Your heart, lungs, liver, and kidneys are functioning adequately **You may NOT be eligible if...** - You are outside the 18–70 age range - Your tumors are CD19-negative - Your organ function does not meet the study requirements - Your overall health is too poor Talk to your doctor to see if this trial is right for you.